|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007787,
umls-concept:C0008976,
umls-concept:C0010068,
umls-concept:C0030705,
umls-concept:C0038454,
umls-concept:C0199176,
umls-concept:C0201950,
umls-concept:C0205309,
umls-concept:C0301630,
umls-concept:C0428466,
umls-concept:C0580822,
umls-concept:C1113667,
umls-concept:C1547300,
umls-concept:C1548760,
umls-concept:C1550594,
umls-concept:C2607943,
umls-concept:C2926606
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-23
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from the standpoint of lipid management. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial included patients with stroke or transient ischemic attack and no known CHD regardless of the presence of carotid atherosclerosis. We evaluated the risk of developing clinically recognized CHD in SPARCL patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1524-4628
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
426-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20110538-Cholesterol,
pubmed-meshheading:20110538-Coronary Disease,
pubmed-meshheading:20110538-Double-Blind Method,
pubmed-meshheading:20110538-Female,
pubmed-meshheading:20110538-Follow-Up Studies,
pubmed-meshheading:20110538-Heptanoic Acids,
pubmed-meshheading:20110538-Humans,
pubmed-meshheading:20110538-Ischemic Attack, Transient,
pubmed-meshheading:20110538-Male,
pubmed-meshheading:20110538-Pyrroles,
pubmed-meshheading:20110538-Stroke
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
|
|
pubmed:affiliation |
Department of Neurology and Stroke Centre, INSERM U-698 and Denis Diderot University-Paris VII, Bichat-Claude Bernard University Hospital, 46 rue Henri Huchard, 75018 Paris, France. pierre@amarenco.net
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
